May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
B7–H1–Mediated Protection of Corneal Endothelial Cells From Killing by Allo–Reactive T Cells in vitro
Author Affiliations & Notes
  • J. Hori
    Ophthalmology, Nippon Medical School, Bunkyo–Ku, Japan
  • M. Miyashita
    Ophthalmology, Nippon Medical School, Bunkyo–Ku, Japan
  • H. Takahashi
    Ophthalmology, Nippon Medical School, Bunkyo–Ku, Japan
  • T. Takemori
    Immunology, National Institute of Infectious Disease, Shinjuku–Ku, Japan
  • H. Yagita
    Immunology, Juntendo University School of Medicine, Bunkyo–Ku, Japan
  • M. Azuma
    Molecular Immunology, Tokyo Medical and Dental University, Bunkyo–Ku, Japan
  • Footnotes
    Commercial Relationships  J. Hori, None; M. Miyashita, None; H. Takahashi, None; T. Takemori, None; H. Yagita, None; M. Azuma, None.
  • Footnotes
    Support  Ministry of Education, Science and Culture, Japan
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 5866. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Hori, M. Miyashita, H. Takahashi, T. Takemori, H. Yagita, M. Azuma; B7–H1–Mediated Protection of Corneal Endothelial Cells From Killing by Allo–Reactive T Cells in vitro . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5866.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Programmed Death–1 (PD–1) / B7–H1 costimulatory pathway has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. We have demonstrated that cornea of normal mouse eyes constitutively express B7–H1, and that PD–1/B7–H1 pathway has a role in corneal allograft survival by inducing apoptosis of infiltrating cells. To further substantiate the B7–H1–mediated protection of corneal allografts from effector T cells, we evaluated the corneal endothelial cell (CEC) destruction by allo–reactive T cells in vitro.

Methods: : Fresh normal cornea from C57BL/6 eyes was incubated with anti–B7–H1 mAb or control rat IgG for 2 h. Magnetic cell sorting and separation was used to purify T cells from the spleen of BALB/c mice that were pre–sensitized by subcutaneous immunization with C57BL/6 spleen cells or with third–party (C3H/He) spleen cells, or from the spleen of naive BALB/c, C57BL/6, or C3H/He mice. The cornea pre–treated with anti–B7–H1 monoclonal antibody (mAb) or control rat IgG was incubated with 2.5x105 T cells. The unfixed corneal samples were incubated with 50 ug/ml propidium iodide (PI) to stain nuclei of dead CEC. PI–positive cells were counted at three randomly selected areas in the corneal endothelium of each corneal sample using confocal microscopy.

Results: : The killing of CEC by allo–reactive T cells in vitro was significantly enhanced in the corneas pre–treated with anti–B7–H1mAb as compared to those pre–treated with control IgG (p=0.0016). Interestingly, B7–H1–mediated protection was also observed after incubation with third–party–reactive T cells (p=0.0248). Moreover, the B7–H1–mediated protection was still observed even after incubation with naive allogeneic T cells (p=0.0051). In contrast, no significant difference was observed between the anti–B7–H1 mAb and control rat IgG–treated corneas when syngeneic C57BL/6 T cells were used as the effector.

Conclusions: : B7–H1 expressed on CEC plays a substantial role in the protection of CEC from destruction by allo–reactive effector T cells. B7–H1 protects cornea from bystander injury by activated T cells. Moreover, constitutive expression of B7–H1 in cornea may inhibit the peripheral sensitization, since naive T cells were sensitized by B7–H1–deficient allogeneic cornea to promote their injury.

Keywords: immune tolerance/privilege • transplantation • immunomodulation/immunoregulation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×